Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2017 Jun 23;19(2):169–175. doi: 10.3233/CBM-160298

HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma

Zijian Zhang a,1, Yanwei Cao b,1, Weiming Zhao a, Lei Guo b, Wanpeng Liu c,*
PMCID: PMC13020721  PMID: 28128740

Abstract

BACKGROUND:

Histone deacetylase 6 (HDAC6) is correlated with poor/better survival from cancers. This study was designed to investigate the correlation between HDAC6 expression and renal cell carcinoma (RCC) patients.

METHODS:

A total of 45 fresh RCC samples and 132 paraffin embedded tissues as well as their corresponding adjacent non-tumor tissues were collected by surgical excision. The qRT-PCR, western blotting analysis and immunohistochemically analysis were performed to detect the expression of HDAC6. Kaplan-Meier curves analysis and Cox proportional hazards model were used to analysis patients survivals as well as to adjust stratification factors.

RESULTS:

The experimental results demonstrated that HDAC6 mRNA expression level was significantly upregulated in RCC tissues compared with adjacent non-tumor tissues, and its expression was correlated with histologic grade and poor overall survival of RCC patients. RCC patients with higher HDAC6 expression showed relative poor survival. Moreover, both HDAC6 expression and histologic grade were correlated with RCC prognosis, and high HDAC6 expression was an independent, poor prognostic factor in patient with RCC.

CONCLUSION:

These analyses showed that high HDAC6 expression was an independent, poor prognostic factor in patients with RCC, and HDAC6 could serve as a biomarker of RCCs prognostic and an indicator for RCC progression.

Keywords: Histone deacetylase 6, renal cell carcinoma, overall survival, prognosis

References

  • [1]. Motzer R.J., Nanus D.M., Russo P. and Berg W.J., Renal cell carcinoma, Current Problems in Cancer, 21 (1997) 185-232. [DOI] [PubMed] [Google Scholar]
  • [2]. Cairns P., Renal cell carcinoma, Cancer Biomarkers, 9 (2011) 461-473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3]. Godley P.A. and Taylor M., Renal cell carcinoma, Current Opinion in Oncology, 13 (2001) 199-203. [DOI] [PubMed] [Google Scholar]
  • [4]. Curti B.D., Renal cell carcinoma, Jama, 292 (2004) 97-100. [DOI] [PubMed] [Google Scholar]
  • [5]. Cohen H.T. and McGovern F.J., Renal-cell carcinoma, New England Journal of Medicine, 353 (2005) 2477-2490. [DOI] [PubMed] [Google Scholar]
  • [6]. Liao S.-Y., Aurelio O.N., Jan K., Zavada J. and Stanbridge E.J., Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney, Cancer Research, 57 (1997) 2827-2831. [PubMed] [Google Scholar]
  • [7]. Thompson R.H., Gillett M.D., Cheville J.C., Lohse C.M., Dong H., Webster W.S., Krejci K.G., Lobo J.R., Sengupta S. and Chen L., Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target, Proceedings of the National Academy of Sciences of the United States of America, 101 (2004) 17174-17179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8]. Redova M., Poprach A., Nekvindova J., Iliev R., Radova L., Lakomy R., Svoboda M., Vyzula R. and Slaby O., Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma, J Transl Med, 10 (2012) 1479-5876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9]. Stypula-Cyrus Y., Damania D., Kunte D.P., Cruz M.D., Subramanian H., Roy H.K. and Backman V., HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure, PLoS One, 8 (2013) e64600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10]. West A.C. and Johnstone R.W., New and emerging HDAC inhibitors for cancer treatment, The Journal of Clinical Investigation, 124 (2014) 30-39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11]. Wagner J.M., Hackanson B., Lübbert M. and Jung M., Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy, Clinical Epigenetics, 1 (2010) 117-136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12]. Göttlicher M., Minucci S., Zhu P., Krãmer O.H., Schimpf A., Giavara S., Sleeman J.P., Coco F.L., Nervi C. and Pelicci P.G., Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells, The EMBO Journal, 20 (2001) 6969-6978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13]. Witt O., Deubzer H.E., Milde T. and Oehme I., HDAC family: What are the cancer relevant targets? Cancer Letters, 277 (2009) 8-21. [DOI] [PubMed] [Google Scholar]
  • [14]. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.-T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B. and Yao T.-P., HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor, Molecular Cell, 18 (2005) 601-607. [DOI] [PubMed] [Google Scholar]
  • [15]. Yang M.H., Laurent G., Bause A.S., Spang R., German N., Haigis M.C. and Haigis K.M., HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS, Molecular Cancer Research, 11 (2013) 1072-1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16]. Lee Y.-S., Lim K.-H., Guo X., Kawaguchi Y., Gao Y., Barrientos T., Ordentlich P., Wang X.-F., Counter C.M. and Yao T.-P., The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis, Cancer Research, 68 (2008) 7561-7569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17]. Boyault C., Sadoul K., Pabion M. and Khochbin S., HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination, Oncogene, 26 (2007) 5468-5476. [DOI] [PubMed] [Google Scholar]
  • [18]. Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., Mita K., Hamaguchi M., Hayashi S.-I. and Iwase H., HDAC6 expression is correlated with better survival in breast cancer, Clinical Cancer Research, 10 (2004) 6962-6968. [DOI] [PubMed] [Google Scholar]
  • [19]. Zuo Q., Wu W., Li X., Zhao L. and Chen W., HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin, Oncology Reports, 27 (2012) 819-824. [DOI] [PubMed] [Google Scholar]
  • [20]. Wang L., Xiang S., Williams K.A., Dong H., Bai W., Nicosia S.V., Khochbin S., Bepler G. and Zhang X., Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells, PLoS One, 7 (2012) e44265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21]. Ramakrishnan S., Ku S., Ciamporcero E., Miles K.M., Attwood K., Chintala S., Shen L., Ellis L., Sotomayor P. and Swetzig W., HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma, BMC Cancer, 16 (2016) 617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22]. Aldana-Masangkay G.I. and Sakamoto K.M., The role of HDAC6 in cancer, Journal of Biomedicine and Biotechnology, 2011 (2011) 1-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23]. Walter C., Kruessell M., Gindele A., Brochhagen H., Gossmann A. and Landwehr P., Imaging of renal lesions: evaluation of fast MRI and helical CT, The British Journal of Radiology, (2014). [DOI] [PubMed] [Google Scholar]
  • [24]. Riolo M.T., Cooper Z.A., Holloway M.P., Cheng Y., Bianchi C., Yakirevich E., Ma L., Chin Y.E. and Altura R.A., Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer, Journal of Biological Chemistry, 287 (2012) 10885-10893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25]. Aldana-Masangkay G.I. and Sakamoto K.M., The role of HDAC6 in cancer, BioMed Research International, 2011 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26]. Yao T.P., Lee Y., Lim K.H., Ordentlich P. and Counter C., A critical role of Histone Deacetylase 6 (HDAC6) in oncogenic transformation, Cancer Research, 68 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27]. Osada H., Tatematsu Y., Saito H., Yatabe Y., Mitsudomi T. and Takahashi T., Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients, International Journal of Cancer, 112 (2004) 26-32. [DOI] [PubMed] [Google Scholar]
  • [28]. Gryder B.E., Sodji Q.H. and Oyelere A.K., Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed, Future Medicinal Chemistry, 4 (2012) 505-524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29]. Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., Mita K., Hamaguchi M., Hayashi S. and Iwase H., HDAC6 expression is correlated with better survival in breast cancer, Clinical Cancer Research an Official Journal of the American Association for Cancer Research, 10 (2004) 6962-6968. [DOI] [PubMed] [Google Scholar]
  • [30]. Ramakrishnan S., Ku S.Y., Swetzig W., Conroy D., Li S., Chintala S., Sotomayor P., Miles K.M., Adelaiye R. and Ciamporcero E., Abstract 4061: Evidence for hdac6 and er-α association in a subset of clear cell renal cell carcinoma, Cancer Research, 74 (2014) 4061-4061. [Google Scholar]
  • [31]. Ramakrishnan S., Ku S., Ciamporcero E., Miles K.M., Attwood K., Chintala S., Shen L., Ellis L., Sotomayor P., Swetzig W., Huang R., Conroy D., Orillion A., Das G. and Pili R., HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma, BMC Cancer, 16 (2016) 617. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES